Aaron Schacht

Aaron Schacht is a seasoned executive in the biotechnology and pharmaceutical industries, serving as Chief Executive Officer and Board Director of BiomEdit since April 2022, focusing on animal health innovations. Schacht holds multiple board roles including Member of the Board of Directors at Gallant Therapeutics and Independent Director at Redux Bio. Their prior tenure at Elanco included positions as Executive Vice President overseeing Animal Health and leading strategic initiatives for microbiome R&D. Schacht has extensive experience in product development and commercialization from their time at Eli Lilly and Company, where Aaron led the launch of the CGRP Neutralizing Antibody, Emgality. The University of Illinois Urbana-Champaign awarded Schacht a Bachelor of Science degree in Chemistry, and earlier education was completed at Pecatonica High School.